Русский
Choice of treatment tactics in patients with acute bacterial intestinal infections who have a high risk of developing irritable bowel syndrome
DOI: https://dx.doi.org/10.18565/epidem.2024.14.2.79-86
Tlyustangelova R.K., Pshenichnaya N.Yu., Lizinfeld I.A., Zhuravlev A.S.
1) Medical Institute, Maikop State Technological University, Maikop, Russia; 2) Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; 3) M. F. Vladimirsky Moscow Regional Research Clinical Institute, Moscow, Russia
Materials and methods. The study included 60 patients with ABIIs aged 18 to 60 years who had a high risk of developing IBS, established using a discriminant equation that included triglyceride, cholesterol and urea levels at the height of the disease. Patients were randomized into 2 groups of 30 individuals each: in the comparison group, standard therapy was prescribed; in the main group, patients additionally received the biologically active dietary supplement zakofalk (250 mg CB and 250 mg I). The effectiveness of therapy was assessed by the triglyceride levels at the height of the disease and at discharge from hospital, fecal calprotectin and I-FABP levels at the height of the disease and 1 month after after discharge.
Results. There were no statistically significant intergroup differences in the duration of the main clinical symptoms and laboratory parameters. However, the fecal calprotectin and I-FABP levels decreased statistically after 1 month after hospital treatment in the main group. Triglyceride levels were also lower during the recovery period in patients of the main group. Incidence of IBS development over the next 6 months was 38.5 times lower in the group receiving BC + I compared with patients receiving standard therapy.
Conclusion. The use of BC + I in addition to standard therapy accelerates the normalization of inflammatory markers and reduces the risk of developing IBS after ABIIs. A biologically active dietary supplement containing BC + I can be considered as an effective mean of preventing the development of IBS in patients with ABII.
Literature
1. Григорович М.С. Функциональное состояние желудочно-кишечного тракта и Особенности исходов при острых кишечных инфекциях. Эпидемиол. и инфекц. бол. 2012; (3): 56–9. Grigorovich M.S. (Functional state of the gastrointestinal tract and outcomes of acute intestinal infections). Epidemiology and Infectious Diseases 2012; (3): 56–9. (In Russ.). 2. Парфенов А.И., Ручкина И.Н., Усенко Д.В. Функциональные болезни кишечника и опыт их лечения продуктами функционального питания. РМЖ. 2007; (1): 29–32. Parfenov A.I., Ruchkina I.N., Usenko D.V. (Functional bowel diseases and the experience of their treatment with functional nutrition products). Russian Medical Journal 2007; (1): 29–32. (In Russ.). 3. Парфенов А.И. Постинфекционный синдром раздраженного кишечника: вопросы лечения и профилактики. Consilium medicum 2002; 4(6): 298–300. Parfenov A.I. (Postinfectious irritable bowel syndrome: issues of treatment and prevention). Consilium medicum 2002; 4(6): 298–300. (In Russ.). 4. McKeown E.S., Parry S.D., Stansfield R., Barton J.R., Welfare M.R. Postinfectious irritable bowel syndrome may occur after non-gastrointestinal and intestinal infection. Neurogastroenterology and Motility 2006; 18(9): 839–43. DOI: 10.1111/j.1365-2982.2006.00821.x 5. Klem F., Wadhwa A., Prokop L.J., Sundt W.J., Farrugia G., Camilleri M. et al. Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: A Systematic Review and Meta-analysis. Gastroenterology 2017; 152(5): 1042–54, e1. DOI: 10.1053/j.gastro.2016.12.039 6. Гаус О.В., Ливзан М.А., Гавриленко Д.А. Постинфекционный синдром раздраженного кишечника: время ренессанса? Медицинский алфавит. 2021; (35): 23–8. DOI: 10.33667/2078-5631-2021-35-23-28 Gaus O.V., Livzan M.A., Gavrilenko D.A. (Post-infectious irritable bowel syndrome: renaissance time?). Medical alphabet 2021; (35): 23–8. (In Russ.). DOI: 10.33667/2078-5631-2021-35-23-28 7. Минушкин О.Н. Новые представления о функциональных расстройствах кишечника и место современных пробиотиков в их лечении. Медицинский совет 2018; (21): 126–31. DOI: 10.21518/2079-701X-2018-21-126-131 Minushkin O.N. (New ideas about functional intestinal disorders and the place of modern probiotics in their treatment). Meditsinsky Sovet 2018; (21): 126–31. (In Russ.). DOI: 10.21518/2079-701X-2018-21-126-131 8. Бутова Е.Н. Оптимизация современной терапии пациентов с синдромом раздраженного кишечника. Лечащий врач 2019; (7): 53–9. DOI: 10.26295/OS.2019.97.32.011 Butova E.N. (Optimizing modern therapy for patients with irritable bowel syndrome). Treating Physician 2019; (7): 53–9. (In Russ.). DOI. 10.26295/OS.2019.97.32.011 9. Сальмонеллез у взрослых 2021–2022–2023: Клинические рекомендации. Утверждены Минздравом РФ. https://cr.minzdrav.gov.ru/recomend/700_2?ysclid=lu4iogcgrd140449563 (Salmonellosis in adults 2021–2022–023: Clinical guidelines). Approved by the Ministry of Health of Russia. (In Russ.). https://cr.minzdrav. gov.ru/recomend/700_2?ysclid=lu4iogcgrd140449563 10. Montalto M., Gallo A., Santoro L., D’Onofrio F., Landolfi R., Gasbarrini A. Role of fecal calprotectin in gastrointestinal disorders. Eur. Rev. Med. Pharmacol. Sci 2013; 17(12): 1569–82. 11. Pelsers M.M., Namiot Z., Kisielewski W., Namiot A., Januszkiewicz M., Hermens W.T. et al. Intestinal-type and liver-type fatty acid-binding protein in the intestine. Tissue distribution and clinical utility. Clin. Biochem. 2003; 36(7): 529–35. DOI: 10.1016/s0009-9120(03)00096-1 12. Uzun O., Turkmen S., Eryigit U., Mentese A., Turkyilmaz S., Turedi S. et al. Can Intestinal Fatty Acid Binding Protein (I-FABP) Be A Marker in the Diagnosis of Abdominal Pathology? Turkish journal of emergency medicine 2016; 14(3): 99–103. DOI: 10.5505/1304.7361.2014. 15679 13. Nakov R., Snegarova V., Dimitrova-Yurukova D., Velikova T. Biomarkers in Irritable Bowel Syndrome: Biological Rationale and Diagnostic Value. Dig. Dis. 2022; 40(1): 23–32. DOI: 10.1159/000516027 14. Helvaci M.R., Altintas E., Canda M.S., Muftuoglu O.E., Abyad A., Pocock L et al. Plasma triglycerides and fasting plasma glucose may behave as sensitive acute phase reactants in irritable bowel syndrome. Middle East Journal of Age and Ageing 2019: 16(1): 7–13. DOI: 10.5742/MEJAA.2019.93631 15. Scarpellini E., Lauritano E.C., Lupascu A., Petruzzellis C., Novi M.L., Roccarina D. et al. Efficacy of butyrate in the treatment of diarrhoea-predominant irritable bowel syndrome. Digestive and Liver Disease Supplements 2007; 1(1): 19–22. DOI: 10.1016/S1594-5804(08) 60006-6 16. Lewandowski K., Kaniewska M., Karłowicz K., Rosołowski M., Rydzewska G. (The effectiveness of microencapsulated sodium butyrate at reducing symptoms in patients with irritable bowel syndrome). Przeglad gastroenterologiczny 2022; 17(1): 28–34. DOI: 10.5114/pg.2021. 112681 17. Tarnowski W., Borycka-Kiciak K., Kiciak A., Friediger J., Cienciała A., Zabielski R. Wyniki leczenia zespołu jelita nadwrażliwego z zastosowaniem kwasu masłowego–raport wstępny. Gastroenterologia Praktyczna 2011; (1): 42–8. (In Polish.). 18. Андреев Д.Н., Кучерявый Ю.А., Черемушкин С.В., Маев И.В. Эффективность включения масляной кислоты в схемы спазмолитической терапии синдрома раздраженного кишечника: метаанализ контролируемых исследований. Consilium Medicum 2020: (8): 27–31. DOI: 10.26442/20751753.2020.8.200194 Andreev D.N., Kucheryavyy Yu.A., Cheremushkin S.V., Maev I.V. (The effectiveness of adding butyric acid to antispasmodic therapy regimens for irritable bowel syndrome: a meta-analysis of controlled studies). Consilium Medicum 2020; 22(8): 27–31. DOI: 10.26442/20751753.2020.8.200194
About the Autors
Roza K. Tlyustangelova, Assistant, Department of Infectious Diseases, Dermatovenereology and Phthisiology, Medical Institute, Maikop State Technological University, Maikop, Russia; tlyustangelova76@mail.ru; http://orcid.org/0000-0002-9926-3964
Professor Natalia Yu. Pshenichnaya, MD, Deputy Director for Clinical and Analytical Work, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being; Professor at the Department of Infectious Diseases, M.F. Vladimirsky Moscow Regional Research Clinical Institute, Moscow, Russia; natalia-pshenichnaya@yandex.ru; https://orcid.org/0000-0003-2570-711X
Irina A. Lizinfeld, Cand. Med. Sci., Consultant, Organizational and Methodological Department, Central Research Institute for Epidemiology of Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; irinalizinfeld@gmail.com; http://orcid.org/ 0000-0002-8114-1002
Andrey S. Zhuravlev, Junior Researcher, Department of X-ray Endovascular Surgery, Department of Endovascular Treatment of Cardiovascular Diseases and Arrhythmias, M.F. Vladimirsky Moscow Regional Research Clinical Institute, Moscow, Russia; zhuravlev_and@inbox.ru; http://orcid.org/0000-0002-9130-707X 129110.
Similar Articles
